Neurocrine Biosciences präsentiert neue zweijährige Daten zu CRENESSITY® mit verbessertem Hormonmanagement bei pädiatrischen Patienten.

Quelle: PR Newswire
Link: https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-two-year-crenessity-crinecerfont-data-demonstrating-durable-hormone-control-reduced-glucocorticoid-exposure-and-meaningful-clinical-improvements-in-pediatric-patients-with-classic-congenital-302759774.html